Hughes TP - Search Results

1

Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo.

Fraser CK, Lousberg EL, Kumar R, Hughes TP, Diener KR, Hayball JD. Fraser CK, et al. Among authors: hughes tp. Exp Hematol. 2009 Dec;37(12):1435-44. doi: 10.1016/j.exphem.2009.09.007. Epub 2009 Sep 26. Exp Hematol. 2009. PMID: 19786067

2

Imatinib inhibits the functional capacity of cultured human monocytes.

Dewar AL, Doherty KV, Hughes TP, Lyons AB. Dewar AL, et al. Among authors: hughes tp. Immunol Cell Biol. 2005 Feb;83(1):48-56. doi: 10.1111/j.1440-1711.2004.01296.x. Immunol Cell Biol. 2005. PMID: 15661041

3

The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.

Blake S, Hughes TP, Mayrhofer G, Lyons AB. Blake S, et al. Among authors: hughes tp. Clin Immunol. 2008 Jun;127(3):330-9. doi: 10.1016/j.clim.2008.02.006. Epub 2008 Apr 18. Clin Immunol. 2008. PMID: 18395492

4

Dasatinib suppresses in vitro natural killer cell cytotoxicity.

Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP. Blake SJ, et al. Among authors: hughes tp. Blood. 2008 Apr 15;111(8):4415-6. doi: 10.1182/blood-2008-02-138701. Blood. 2008. PMID: 18398058 Free article. No abstract available.

5

Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.

Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD. Fraser CK, et al. Among authors: hughes tp. Exp Hematol. 2009 Feb;37(2):256-65. doi: 10.1016/j.exphem.2008.09.013. Epub 2008 Dec 3. Exp Hematol. 2009. PMID: 19056158 Free article.

6

Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo.

Fraser CK, Lousberg EL, Guerin LR, Hughes TP, Brown MP, Diener KR, Hayball JD. Fraser CK, et al. Among authors: hughes tp. Cancer Biol Ther. 2010 Oct 1;10(7):715-27. doi: 10.4161/cbt.10.7.12926. Epub 2010 Oct 1. Cancer Biol Ther. 2010. PMID: 20676039

7

Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A.

Blake SJ, Hughes TP, Lyons AB. Blake SJ, et al. Among authors: hughes tp. Exp Hematol. 2012 Aug;40(8):612-21.e6. doi: 10.1016/j.exphem.2012.04.003. Epub 2012 Apr 19. Exp Hematol. 2012. PMID: 22521768 Free article.

8

Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.

Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP, Lyons AB. Dewar AL, et al. Among authors: hughes tp. Blood. 2005 Apr 15;105(8):3127-32. doi: 10.1182/blood-2004-10-3967. Epub 2005 Jan 6. Blood. 2005. PMID: 15637141 Free article.

9

Inhibition of c-fms by imatinib: expanding the spectrum of treatment.

Dewar AL, Zannettino AC, Hughes TP, Lyons AB. Dewar AL, et al. Among authors: hughes tp. Cell Cycle. 2005 Jul;4(7):851-3. doi: 10.4161/cc.4.7.1788. Epub 2005 Jul 28. Cell Cycle. 2005. PMID: 15917650

10

Strategies for the treatment of imatinib-resistant chronic myeloid leukemia.

Hui CH, Hughes TP. Hui CH, et al. Among authors: hughes tp. Clin Adv Hematol Oncol. 2003 Sep;1(9):538-45, 559. Clin Adv Hematol Oncol. 2003. PMID: 16258446 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

368 results

Search Page